Alivus Life Sciences Limited (NSE:ALIVUS)

Market Cap	131.09B +6.5%
Revenue (ttm)	25.12B +10.5%
Net Income	5.44B +23.1%
EPS	44.23 +23.1%
Shares Out	122.74M
PE Ratio	24.15
Forward PE	21.60
Dividend	5.00 (0.47%)
Ex-Dividend Date	Sep 1, 2025

Volume	156,114
Average Volume	100,822
Open	1,069.35
Previous Close	1,068.05
Day's Range	1,042.25 - 1,088.00
52-Week Range	819.00 - 1,225.10
Beta	0.01
RSI	79.07
Earnings Date	May 15, 2026

About Alivus Life Sciences

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,203
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ALIVUS

Financial Performance

In fiscal year 2025, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.